AAPL 238.8 3.8893% MSFT 445.64 2.5497% NVDA 126.645 6.9456% GOOGL 195.01 1.6683% GOOG 196.71 1.5173% AMZN 239.22 1.6141% META 679.365 2.9528% AVGO 203.53 0.6926% LLY 807.205 -0.1194% TSLA 393.3501 -0.9568% TSM 199.39 3.6816% V 337.31 0.828% JPM 266.12 0.1016% UNH 541.75 -0.3257% NVO 84.74 -3.1654% WMT 97.4648 0.0665% LVMUY 152.0 -4.252% XOM 108.17 -1.8154% LVMHF 765.0 -3.7433% MA 549.66 0.3689%
Last update at 2025-01-28T18:52:00Z
Zoetis Inc. (NYSE:ZTS) Delivered A Better ROE Than Its Industry
Tue 21 Jan 25, 01:00 PMInvestors in Zoetis (NYSE:ZTS) have unfortunately lost 18% over the last three years
Fri 10 Jan 25, 02:00 PMZoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
Wed 08 Jan 25, 11:15 PMIs Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?
Tue 07 Jan 25, 09:15 PMAn Intrinsic Calculation For Zoetis Inc. (NYSE:ZTS) Suggests It's 34% Undervalued
Fri 03 Jan 25, 11:00 AMIs Zoetis Inc. (ZTS) the Best Pharma Dividend Stock to Buy In 2024?
Mon 30 Dec 24, 09:31 PMZoetis (ZTS) is a Top-Ranked Growth Stock: Should You Buy?
Mon 30 Dec 24, 02:45 PMZoetis Inc. (ZTS): A Bull Case Theory
Thu 26 Dec 24, 04:35 PMZoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase
Thu 12 Dec 24, 09:15 PMWill Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Mon 21 Oct 24, 04:10 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 2656.00M | 2488.00M | 1996.00M | 1801.00M | 1690.00M |
| Minority interest | 3.00M | -3.00000M | -2.00000M | 4.00M | -4.00000M |
| Net income | 2114.00M | 2037.00M | 1638.00M | 1500.00M | 1428.00M |
| Selling general administrative | 2009.00M | 2001.00M | 1726.00M | 1638.00M | 1484.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 5626.00M | 5473.00M | 4618.00M | 4268.00M | 3914.00M |
| Reconciled depreciation | 465.00M | 161.00M | 441.00M | 412.00M | 308.00M |
| Ebit | 2888.00M | 2755.00M | 2288.00M | 2075.00M | 1964.00M |
| Ebitda | 3038.00M | 2916.00M | 2729.00M | 2230.00M | 2081.00M |
| Depreciation and amortization | 150.00M | 161.00M | 441.00M | 155.00M | 117.00M |
| Non operating income net other | -40.00000M | -48.00000M | -17.00000M | 57.00M | 83.00M |
| Operating income | 2888.00M | 2755.00M | 2288.00M | 2075.00M | 1881.00M |
| Other operating expenses | 5152.00M | 4973.00M | 4406.00M | 4242.00M | 3944.00M |
| Interest expense | 221.00M | 224.00M | 231.00M | 223.00M | 206.00M |
| Tax provision | 545.00M | 454.00M | 360.00M | 301.00M | 266.00M |
| Interest income | 50.00M | 6.00M | 12.00M | 37.00M | 31.00M |
| Net interest income | -171.00000M | -224.00000M | -219.00000M | -186.00000M | -175.00000M |
| Extraordinary items | - | - | - | - | 45.00M |
| Non recurring | 11.00M | 43.00M | 25.00M | 51.00M | 68.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 545.00M | 454.00M | 360.00M | 301.00M | 266.00M |
| Total revenue | 8080.00M | 7776.00M | 6675.00M | 6260.00M | 5825.00M |
| Total operating expenses | 2698.00M | 2670.00M | 2349.00M | 2250.00M | 2033.00M |
| Cost of revenue | 2454.00M | 2303.00M | 2057.00M | 1992.00M | 1911.00M |
| Total other income expense net | -232.00000M | -267.00000M | -292.00000M | -274.00000M | 15.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 2111.00M | 2034.00M | 1636.00M | 1500.00M | 1424.00M |
| Net income applicable to common shares | 2114.00M | 2037.00M | 1638.00M | 1500.00M | 1428.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 14925.00M | 13900.00M | 13609.00M | 11545.00M | 10777.00M |
| Intangible assets | 1380.00M | 1474.00M | 1710.00M | 1890.00M | 2046.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 365.00M | 389.00M | 366.00M | 318.00M | 271.00M |
| Total liab | 10522.00M | 9356.00M | 9836.00M | 8837.00M | 8592.00M |
| Total stockholder equity | 4405.00M | 4543.00M | 3769.00M | 2708.00M | 2185.00M |
| Deferred long term liab | 142.00M | 320.00M | 378.00M | 434.00M | 474.00M |
| Other current liab | 1410.00M | 1361.00M | 93.00M | 55.00M | 866.00M |
| Common stock | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M |
| Capital stock | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M |
| Retained earnings | 8668.00M | 7186.00M | 5659.00M | 4427.00M | 3270.00M |
| Other liab | 585.00M | 811.00M | 891.00M | 917.00M | 926.00M |
| Good will | 2746.00M | 2682.00M | 2694.00M | 2592.00M | 2519.00M |
| Other assets | 320.00M | 211.00M | 392.00M | 160.00M | 147.00M |
| Cash | 3577.00M | 3482.00M | 3602.00M | 1932.00M | 1602.00M |
| Cash and equivalents | 3577.00M | 3482.00M | 3602.00M | 1932.00M | 1602.00M |
| Total current liabilities | 3167.00M | 1797.00M | 2170.00M | 1806.00M | 1223.00M |
| Current deferred revenue | - | - | 1016.00M | 950.00M | 35.00M |
| Net debt | 4513.00M | 3261.00M | 3760.00M | 4679.00M | 4850.00M |
| Short term debt | 1352.00M | 0.00000M | 604.00M | 500.00M | 9.00M |
| Short long term debt | 1352.00M | - | 604.00M | 500.00M | 9.00M |
| Short long term debt total | 8090.00M | 6743.00M | 7362.00M | 6611.00M | 6452.00M |
| Other stockholder equity | -3451.00000M | -1884.00000M | -1165.00000M | -998.00000M | -461.00000M |
| Property plant equipment | 2753.00M | 2422.00M | 2202.00M | 1940.00M | 1658.00M |
| Total current assets | 7506.00M | 6930.00M | 6611.00M | 4748.00M | 4399.00M |
| Long term investments | - | - | - | 26.00M | 8.00M |
| Net tangible assets | 279.00M | 387.00M | -635.00000M | -1774.00000M | -2357.00000M |
| Short term investments | - | - | - | 0.00000M | 99.00M |
| Net receivables | 1215.00M | 1133.00M | 1013.00M | 1086.00M | 1036.00M |
| Long term debt | 6552.00M | 6592.00M | 6595.00M | 5947.00M | 6443.00M |
| Inventory | 2345.00M | 1923.00M | 1628.00M | 1410.00M | 1391.00M |
| Accounts payable | 405.00M | 436.00M | 457.00M | 301.00M | 313.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | -2.00000M | 1.00M | 4.00M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -817.00000M | -764.00000M | -730.00000M | -726.00000M | -629.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 8668.00M | 7186.00M | 5659.00M | 4427.00M | 3270.00M |
| Treasury stock | -4539.00000M | -2952.00000M | -2230.00000M | -2042.00000M | -1487.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 147.00M | 111.00M | 106.00M | 98.00M | 94.00M |
| Deferred long term asset charges | - | - | - | 88.00M | 61.00M |
| Non current assets total | 7419.00M | 6970.00M | 6998.00M | 6797.00M | 6378.00M |
| Capital lease obligations | 186.00M | 151.00M | 163.00M | 164.00M | - |
| Long term debt total | 6552.00M | 6592.00M | 6595.00M | 5947.00M | 6443.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -883.00000M | 32.00M | -27.00000M | 138.00M | 28.00M |
| Change to liabilities | -111.00000M | 185.00M | 255.00M | 73.00M | 160.00M |
| Total cashflows from investing activities | -883.00000M | -458.00000M | -572.00000M | -504.00000M | -2259.00000M |
| Net borrowings | 1340.00M | -604.00000M | 732.00M | -9.00000M | 1493.00M |
| Total cash from financing activities | -904.00000M | -1862.00000M | 123.00M | -951.00000M | 533.00M |
| Change to operating activities | -47.00000M | 195.00M | 40.00M | 32.00M | 81.00M |
| Net income | 2111.00M | 2034.00M | 1636.00M | 1500.00M | 1424.00M |
| Change in cash | 96.00M | -119.00000M | 1670.00M | 332.00M | 38.00M |
| Begin period cash flow | 3485.00M | 3604.00M | 1934.00M | 1602.00M | 1564.00M |
| End period cash flow | 3581.00M | 3485.00M | 3604.00M | 1934.00M | 1602.00M |
| Total cash from operating activities | 1912.00M | 2213.00M | 2126.00M | 1795.00M | 1790.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 465.00M | 448.00M | 441.00M | 412.00M | 308.00M |
| Other cashflows from investing activities | -311.00000M | -13.00000M | -92.00000M | -182.00000M | -1949.00000M |
| Dividends paid | -611.00000M | -474.00000M | -380.00000M | -314.00000M | 243.00M |
| Change to inventory | -486.00000M | -366.00000M | -346.00000M | -104.00000M | 61.00M |
| Change to account receivables | -137.00000M | -155.00000M | 74.00M | -69.00000M | -67.00000M |
| Sale purchase of stock | -1594.00000M | -743.00000M | -250.00000M | -626.00000M | -698.00000M |
| Other cashflows from financing activities | 1311.00M | -6.00000M | 9.00M | -11.00000M | 1474.00M |
| Change to netincome | -82.00000M | 71.00M | 137.00M | 31.00M | -57.00000M |
| Capital expenditures | 586.00M | 477.00M | 453.00M | 460.00M | 338.00M |
| Change receivables | -137.00000M | -155.00000M | 74.00M | -69.00000M | -67.00000M |
| Cash flows other operating | 152.00M | -4.00000M | -71.00000M | -48.00000M | -39.00000M |
| Exchange rate changes | - | - | - | -8.00000M | -26.00000M |
| Cash and cash equivalents changes | 125.00M | -107.00000M | 1677.00M | 332.00M | 38.00M |
| Change in working capital | -699.00000M | -343.00000M | -85.00000M | -151.00000M | 112.00M |
| Stock based compensation | 62.00M | 58.00M | 59.00M | 67.00M | 53.00M |
| Other non cash items | 259.00M | 96.00M | 137.00M | 46.00M | 5.00M |
| Free cash flow | 1326.00M | 1736.00M | 1673.00M | 1335.00M | 1452.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ZTS Zoetis Inc |
-1.66 0.96% | 171.37 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.79 2.59% | 31.32 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 148.00 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.005 0.04% | 13.36 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
0.004 0.02% | 24.94 | 32.60 | 11.59 | 0.01 | 0.88 | 0.02 | 0.07 |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
10 Sylvan Way, Parsippany, NJ, United States, 07054
| Name | Title | Year Born |
|---|---|---|
| Ms. Kristin C. Peck | CEO & Director | 1971 |
| Mr. Wetteny N. Joseph | Exec. VP & CFO | 1972 |
| Ms. Heidi C. Chen | Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics | 1967 |
| Mr. Glenn C. David | Exec. VP & Group Pres of U.S. Operations, Global Diagnostics and BioDevices | 1972 |
| Ms. Roxanne Lagano | Exec. VP and Chief HR Officer & Global Operations | 1965 |
| Ms. Wafaa Mamilli | EVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal Health | 1967 |
| Mr. Steven Frank | VP of Investor Relations | NA |
| Mr. William Price | VP & Chief Communications Officer | NA |
| Dr. Robert J. Polzer Ph.D. | Exec. VP and Pres of R&D | 1969 |
| Ms. Jeannette Ferran Astorga | Exec. VP of Corp. Affairs & Communications and Chief Sustainability Officer | 1975 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...